NCT05001971View on ClinicalTrials.gov

Anlotinib Plus Penpulimab for the Treatment of Sensitive Relapsed Small-Cell Lung Cancer

PHASE2UnknownINTERVENTIONAL
Enrollment

73

Participants

Timeline

Start Date

December 28, 2020

Primary Completion Date

June 30, 2023

Study Completion Date

December 31, 2023

Conditions
Small Cell Lung Cancer
Interventions
DRUG

Anlotinib Plus Penpulimab

Anlotinib: 10mg orally daily on day 1 to 14 of a 21-day cycle. Penpulimab: 200mg by intravenous drip on day 1 of a 21-day cycle.

Trial Locations (1)

410000

RECRUITING

Nong Yang, Changsha

Sponsors
All Listed Sponsors
collaborator

Fuzhou Pulmonary Hospital of Fujian

OTHER

collaborator

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

INDUSTRY

lead

Hunan Cancer Hospital

OTHER